Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based biotechnology start-up Forge Therapeutics has entered into a pilot study with Janssen Research & Development (JRD) to examine the Forge's chemistry platform in the discovery of new metalloprotein inhibitors.
Subscribe to our email newsletter
The study will use Forge’s expertise and intellectual property in the field of metalloprotein inhibitor discovery, while the company will receive funding support from JRD.
Forge Therapeutics CEO Zachary Zimmerman said: "At Forge Therapeutics we are excited to investigate the potential of targeting metalloproteins, which make up over one-third of the proteins in our body, to develop a new and novel class of small molecule inhibitors to treat a wide range of diseases.
"We kicked-off operations earlier this year in JLABS and within a few months we are entering into a pilot study with JRD to investigate our metalloprotein chemistry, and we believe large pharmaceutical companies can benefit from Forge’s approach and platform to bring novel chemistry to validated biological targets."
Forge leverages its new chemistry platform to develop small molecule inhibitors to target metalloproteins, which are proteins that require metal ions for their biological function and make up over 1/3 of the proteins in the human body.
The company uses a proprietary approach comprised of molecular modeling for rational drug design along with fundamental knowledge and expertise in bioinorganic chemistry to target metalloproteins.